secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K/A
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001193125-24-256576
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics Q3 rev $18.5M (+4% YoY); cash flow breakeven shifted to Q3 2025
---------------------------------------------------------------------------

- Q3 revenue $18.5M (+4% vs Q3 2023); U.S. system revenue $4.1M (+14%), treatment session revenue $13.3M (+2%).
- Net loss $(13.3)M ($(0.44)/share) vs $(9.4)M ($(0.33)/share) in Q3 2023; EBITDA $(11.6)M.
- Shareholders approved all-stock Greenbrook TMS acquisition; expects cash flow breakeven by Q3 2025 (corrected from Q2).
- Q4 2024 standalone revenue guidance $19M-$20M; full-year 2024 guidance $71M-$72M.
- 188,000 patients treated globally; NeuroStar adolescent TMS data showed 78% response rate at AACAP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000119312524256576/0001193125-24-256576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000119312524256576/d885367d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-256576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer